---
title: "Hepatic resection for colorectal cancer liver metastasis"
slug: "hepatic-resection-for-colorectal-cancer-liver-metastasis"
date: "2023-08-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Metastatic Colon Cancer]]

# Hepatic resection for colorectal cancer liver metastasis

- Approximately 153,000 patients are newly diagnosed with colorectal cancer (CRC) in the United States annually [1]. Among those who develop liver metastases, approximately 20 percent will be candidates for potentially curative liver resection.
- åœ¨ç¾åœ‹ï¼Œæ¯å¹´ç´„æœ‰ 153ï¼Œ000 ä¾‹æ–°è¨ºæ–·ç‚ºçµç›´è…¸ç™Œ (CRC) çš„ â†’ æ‚£è€…[1]
- åœ¨ç™¼ç”Ÿè‚è½‰ç§»çš„ â†’ æ‚£è€…ä¸­ï¼Œå¤§ç´„ 20%çš„ â†’ äººå¯èƒ½é©åˆé€²è¡Œæ²»ç™’æ€§è‚åˆ‡é™¤è¡“ã€‚
- Long-term survival after surgery for colorectal liver metastases (CRLMs) has improved dramatically, with five-year overall survival (OS) rates doubling from approximately 30 percent in the 1980s to 1990s to almost 60 percent in the last two decades.
- çµç›´è…¸è‚è½‰ç§»ç˜¤ (CRLM) æ‰‹è¡“å¾Œçš„ â†’ é•·æœŸç”Ÿå­˜ç‡é¡¯è‘—æ”¹å–„ï¼Œäº”å¹´ç¸½ç”Ÿå­˜ç‡ (OS) å¾ 1980 å¹´ä»£è‡³ 1990 å¹´ä»£çš„ â†’ ç´„ 30%ç¿»äº†ä¸€ç•ªï¼Œåœ¨éå»äºŒåå¹´ä¸­æ¥è¿‘ 60%ã€‚
-

# We agree with guidelines developed from a consensus conference held by the American Hepato-Pancreato-Biliary Association, the Society for Surgery of the Alimentary Tract, and the Society of Surgical Oncology in 2006, which state [11]

æˆ‘å€‘åŒæ„ç¾åœ‹è‚èƒ°è†½å”æœƒã€æ¶ˆåŒ–é“å¤–ç§‘å­¸æœƒå’Œè…«ç˜¤å¤–ç§‘å­¸æœƒæ–¼ 2006 å¹´å¬é–‹çš„ â†’ å…±è­˜æœƒè­°åˆ¶å®šçš„ â†’ æŒ‡å—ï¼Œå…¶ä¸­æŒ‡å‡º[11]ï¼š

- In patients undergoing liver resection for hepatic colorectal metastases, a positive surgical margin is â†’ associated with a higher local recurrence and worse OS and should be avoided whenever possible.
  åœ¨å› è‚çµç›´è…¸è½‰ç§»è€Œæ¥å—è‚åˆ‡é™¤è¡“çš„ â†’ æ‚£è€…ä¸­ï¼Œæ‰‹è¡“åˆ‡ç·£é™½æ€§èˆ‡è¼ƒé«˜çš„ â†’ å±€éƒ¨å¾©ç™¼ç‡å’Œæ›´å·®çš„ â†’ OS ç›¸é—œï¼Œæ‡‰ç›¡å¯èƒ½ â˜¢ é¿å…ã€‚

- While a wide (>1 cm) resection margin should remain the goal when performing a liver resection, an anticipated margin of <1 cm should not be used as an exclusion criterion for resection. (See 'Wide versus narrow margin' below.)
  é›–ç„¶åœ¨é€²è¡Œè‚åˆ‡é™¤è¡“æ™‚ï¼Œå¯¬åˆ‡ç·£ (>1 cm) æ‡‰ä»ç„¶æ˜¯ç›®æ¨™ï¼Œä½† âœ– ä¸æ‡‰å°‡é æœŸçš„ â†’ åˆ‡ç·£<1 cm ä½œç‚ºåˆ‡é™¤çš„ â†’ æ’é™¤æ¨™æº–ã€‚ (åƒè¦‹ä¸‹æ–‡'å¯¬é‚Šè·èˆ‡çª„é‚Šè·')

- Assessment of resectability of hepatic colorectal metastases should focus on the ability to obtain a complete resection (negative margins).
  è‚çµç›´è…¸è½‰ç§»ç˜¤å¯åˆ‡é™¤æ€§çš„ â†’ è©•ä¼°æ‡‰å´é‡æ–¼ç²å¾—å®Œå…¨åˆ‡é™¤è¡“ (é™°æ€§åˆ‡ç·£) çš„ â†’ èƒ½åŠ›ã€‚

- The feasibility of hepatic resection should also be based on three criteria related to the remaining liver following resection: (1) the ability to preserve two contiguous hepatic segments, (2) preservation of adequate vascular inflow and outflow as well as biliary drainage, and (3) the ability to preserve adequate future liver remnant (>20 percent in a healthy liver; >30 percent after chemotherapy). (See "Overview of hepatic resection", section on 'Contraindications'.)
  è‚åˆ‡é™¤è¡“çš„ â†’ å¯è¡Œæ€§é‚„æ‡‰åŸºæ–¼èˆ‡åˆ‡é™¤å¾Œå‰©é¤˜è‚è‡Ÿç›¸é—œçš„ â†’ ä¸‰å€‹æ¨™æº–ï¼š (1) ä¿ç•™å…©å€‹ç›¸é„°è‚æ®µçš„ â†’ èƒ½åŠ›ï¼Œ (2) ä¿ç•™è¶³å¤ çš„ â†’ è¡€ç®¡æµå…¥å’Œæµå‡ºä»¥åŠè†½é“å¼•æµï¼Œä»¥åŠ (3) ä¿ç•™è¶³å¤ çš„ â†’ æœªä¾†è‚è‡Ÿæ®˜ç•™ç‰©çš„ â†’ èƒ½åŠ› (å¥åº·è‚è‡Ÿä¸­>20%;åŒ–ç™‚å¾Œ>30%) ã€‚ (åƒè¦‹ â€œè‚åˆ‡é™¤æ¦‚è¿°â€ï¼Œé—œæ–¼'ç¦å¿Œè­‰'ä¸€ç¯€)

- The presence of extrahepatic disease should no longer be considered an absolute contraindication to hepatic resection provided the patient is â†’ carefully selected and a complete (margin-negative) resection of both intra- and extrahepatic disease is â†’ feasible.
  è‚å¤–ç–¾ç—…çš„ â†’ å­˜åœ¨ âœ– ä¸æ‡‰å†è¢«è¦–ç‚ºè‚åˆ‡é™¤è¡“çš„ â†’ çµ•å°ç¦å¿Œè­‰ï¼Œå‰ææ˜¯æ‚£è€…ç¶“éç²¾å¿ƒé¸æ“‡ï¼Œä¸¦ä¸”å®Œå…¨ (åˆ‡ç·£é™°æ€§) åˆ‡é™¤è‚å…§å’Œè‚å¤–ç–¾ç—…æ˜¯å¯è¡Œçš„ â†’ ã€‚

Specific to the last point, portohepatic lymph node metastases associated with CRLMs are no longer considered an absolute contraindication to surgery [12-16]. Outcomes are more favorable when nodal involvement is â†’ limited to the porta hepatis nodes, as opposed to the common hepatic artery or paraaortic nodes [13].
å…·é«”åˆ°æœ€å¾Œä¸€é»ï¼Œèˆ‡ CRLM ç›¸é—œçš„ â†’ é–€éœè„ˆæ·‹å·´çµè½‰ç§» âœ– ä¸å†è¢«èªç‚ºæ˜¯æ‰‹è¡“çš„ â†’ çµ•å°ç¦å¿Œè­‰[12-16]

- èˆ‡è‚ç¸½å‹•è„ˆæˆ–ä¸»å‹•è„ˆæ—çµç›¸æ¯”ï¼Œæ·‹å·´çµå—ç´¯åƒ…é™æ–¼è‚ç‚é–€æ·‹å·´çµæ™‚ï¼Œçµå±€æ›´æœ‰åˆ©[13]ã€‚
- 

## NEOADJUVANT CHEMOTHERAPY

[[RECIST]] (Response Evaluation Criteria in Solid Tumors
